Express Scripts · MOUD Buprenorphine Sublocade · US health-plan appeal rights

MOUD Buprenorphine Sublocade denied for failing step therapy by Express Scripts?

Q: How long do I have to appeal a Express Scripts MOUD Buprenorphine Sublocade denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-25

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Express Scripts typically requires

Sublocade requires 7+ days sublingual buprenorphine stabilization before LA injectable approved.

Source policy: Express Scripts SUD Coverage Policy — Sublocade Step Therapy

What works in the appeal

Patient-specific justification: prior buprenorphine non-adherence, diversion concerns, work/travel adherence challenges, prior overdose, pregnancy. ASAM NPG OUD 2020. Cite HOFER pivotal (Haight 2019, Lancet). MHPAEA 2024 Final Rule NQTL — demand comparative analysis.

The Express Scripts angle on MOUD Buprenorphine Sublocade

## Why Express Scripts Applies Step Therapy to Sublocade — and How to Challenge It

Express Scripts (ESI) and its client health plans frequently require patients to try and fail one or more preferred MOUD agents — typically sublingual buprenorphine film or tablet — before approving Sublocade (buprenorphine extended-release subcutaneous injection). The plan's position is that the oral/sublingual formulation is clinically equivalent and less costly, making it the appropriate first-line agent under the formulary's step-therapy protocol.

This logic has clinical limits. Extended-release injectable buprenorphine is not simply a more expensive version of the same drug: it eliminates daily oral dosing, reduces diversion risk, addresses certain adherence patterns, and may be the medically appropriate first choice for specific patients. Step-therapy denials for Sublocade are challengeable on both clinical and legal grounds, including federal parity law (MHPAEA) and most states' step-therapy exception statutes.

## Federal and Legal Framework

MHPAEA parity: ESI cannot apply step-therapy requirements to substance use disorder treatments that are more restrictive than comparable requirements for medical/surgical benefits. If the step-therapy protocol for Sublocade has no comparable parallel in the medical benefit, document this as a parity violation.
State step-therapy exception laws: Most states require plans to grant an exception when: (a) the required step drug was previously tried and failed, (b) the step drug is clinically contraindicated or inappropriate, or (c) applying the step would cause clinically significant delay or risk.
Internal appeal (ACA §2719 / ERISA §503): File within 180 days of denial. Plans must respond within 30 days (pre-service) or 60 days (post-service).
Expedited review: Request within 72 hours if the standard timeline endangers the patient's treatment continuity or health.
External independent review (ACA §2719): Approximately four months from the denial to initiate. Step-therapy denials that involve parity arguments or documented prior failures are strong candidates for external reversal.

## The Appeal Process

1. Obtain ESI's published step-therapy criteria for Sublocade and identify the required step(s). 2. Determine which exception pathway applies: prior failure of the step drug, contraindication, or clinical urgency. 3. Identify the applicable state step-therapy exception statute and cite it by name in the appeal. 4. File a written internal appeal invoking the exception, with full documentation. 5. File for external review if the internal appeal is denied — raise the parity argument at both stages.

## Documentation to Gather

Diagnosis confirmation: DSM-5 opioid use disorder diagnosis, severity specifier, date, and treating clinician.
Step-drug trial history: For sublingual buprenorphine (or other required step agents) — dates of trial, clinical outcomes, reason for transition (insufficient response, adherence failure, diversion risk, patient-specific factors), documented in chart notes.
Clinical rationale for Sublocade: Prescriber letter explaining why the extended-release injectable formulation is medically appropriate for this individual, referencing FDA-approved prescribing information and ASAM/SAMHSA guidelines generically.
Parity analysis: A statement that the step-therapy requirement is being applied to an addiction treatment medication and that comparable step requirements do not appear to apply to analogous medical/surgical treatments under the same plan.
Exception basis documentation: Chart notes and prescriber attestation supporting the specific exception being claimed (prior failure, contraindication, or urgency).

## Criteria-Mapping Structure

| ESI Step Requirement | Patient-Specific Response | |---|---| | Trial of sublingual buprenorphine required | [Dates, dose range, clinical outcome, reason for transition] | | Exception: prior failure of step drug | [Chart documentation of failure with dates] | | Exception: step drug clinically inappropriate | [Prescriber attestation with clinical rationale] | | Exception: clinical urgency | [Documentation of risk from delay] | | Sublocade medically necessary | [Prescriber letter; ASAM/SAMHSA guideline reference] |

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other insurers on MOUD Buprenorphine Sublocade

UnitedHealthcare denied for failing step therapy of MOUD Buprenorphine Sublocade

Other denial reasons for Express Scripts MOUD Buprenorphine Sublocade

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.